Liraglutide alleviates myocardial ischemia‒reperfusion injury in diabetic mice

[1]  Fen Liu,et al.  Targeted activation of ERK1/2 reduces ischemia and reperfusion injury in hyperglycemic myocardium by improving mitochondrial function , 2022, Annals of translational medicine.

[2]  Zelin Li,et al.  Independent and combined effects of liraglutide and aerobic interval training on glycemic control and cardiac protection in diabetic cardiomyopathy rats. , 2022, Biochemical and biophysical research communications.

[3]  T. Zhang,et al.  Cardiac fibroblast heat shock protein 47 aggravates cardiac fibrosis post myocardial ischemia–reperfusion injury by encouraging ubiquitin specific peptidase 10 dependent Smad4 deubiquitination , 2022, Acta pharmaceutica Sinica. B.

[4]  Guandong Wang.  Aerobic exercise ameliorates myocardial ischemia/reperfusion injury and thrombosis of diabetic rats via activation of AMPK/Sirt1/PGC-1α pathway. , 2022, General physiology and biophysics.

[5]  Yangang Xing,et al.  Blunting TRPML1 channels protects myocardial ischemia/reperfusion injury by restoring impaired cardiomyocyte autophagy , 2022, Basic Research in Cardiology.

[6]  Y. Wang,et al.  Novel dual glucagon-like peptide-1/ glucose-dependent insulinotropic polypeptide receptor agonist attenuates diabetes and myocardial injury through inhibiting hyperglycemia, inflammation and oxidative stress in rodent animals , 2022, Bioengineered.

[7]  J. Qin,et al.  Therapeutic effects and mechanism of liraglutide on rats with type 2 diabetes and metabolic-associated fatty liver disease. , 2022, Endocrine, Metabolic & Immune Disorders - Drug Targets.

[8]  Y. Leng,et al.  Activation of NRF2/FPN1 pathway attenuates myocardial ischemia–reperfusion injury in diabetic rats by regulating iron homeostasis and ferroptosis , 2021, Cell Stress and Chaperones.

[9]  Jian-Jun Meng,et al.  HSP90-Mediates Liraglutide Preconditioning-Induced Cardioprotection by Inhibiting C5a and NF-κB , 2021, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

[10]  D. Koya,et al.  Autophagy in metabolic disease and ageing , 2021, Nature Reviews Endocrinology.

[11]  Yiping Li,et al.  Role of epigenetic regulation in myocardial ischemia/reperfusion injury. , 2021, Pharmacological research.

[12]  T. Kitamura,et al.  Leucine imparts cardioprotective effects by enhancing mTOR activity and mitochondrial fusion in a myocardial ischemia/reperfusion injury murine model , 2021, Diabetology & Metabolic Syndrome.

[13]  Roy Taylor,et al.  Effect of Weight Loss by Low-Calorie Diet on Cardiovascular Health in Type 2 Diabetes: An Interventional Cohort Study , 2021, Nutrients.

[14]  C. Torregroza,et al.  Combination of Cyclosporine A and Levosimendan Induces Cardioprotection under Acute Hyperglycemia , 2021, International journal of molecular sciences.

[15]  Xuan Jing,et al.  Liraglutide preconditioning attenuates myocardial ischemia/ reperfusion injury via homer1 activation , 2021, Aging.

[16]  Jian Li,et al.  Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis , 2021, Protein & cell.

[17]  Min Zhang,et al.  GAS5 regulates diabetic cardiomyopathy via miR-221-3p/p27 axis-associated autophagy , 2020, Molecular medicine reports.

[18]  K. Khunti,et al.  Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trial , 2021, Diabetes, obesity & metabolism.

[19]  R. Kelishadi.  Liraglutide for management of adolescent obesity , 2020, Nature Reviews Endocrinology.

[20]  J. Sadoshima,et al.  Upregulation of Rubicon promotes autosis during myocardial ischemia/reperfusion injury. , 2020, The Journal of clinical investigation.

[21]  Y. Birnbaum,et al.  Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK–mTOR Interplay , 2020, Cardiovascular Drugs and Therapy.

[22]  B. Zinman,et al.  Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials , 2020, Diabetes, obesity & metabolism.

[23]  G. Filippatos,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2020, European heart journal.

[24]  Dongmei Wang,et al.  The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases , 2019, Cells.

[25]  S. Verma,et al.  Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial. , 2019, JAMA cardiology.

[26]  L. Cai,et al.  Protective effects of sulforaphane on type 2 diabetes-induced cardiomyopathy via AMPK-mediated activation of lipid metabolic pathways and NRF2 function. , 2019, Metabolism: clinical and experimental.

[27]  F. Cosentino,et al.  The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.

[28]  Yunlong Bai,et al.  Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy , 2019, International journal of biological sciences.

[29]  Xuan Sun,et al.  Mesenchymal stromal cell-derived exosomes attenuate myocardial ischaemia-reperfusion injury through miR-182-regulated macrophage polarization , 2019, Cardiovascular research.

[30]  Deepak L. Bhatt,et al.  Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke: Post Hoc Analysis From the LEADER Trial , 2018, Circulation.

[31]  F. Prinzen,et al.  Editor’s Choice- Reperfusion cardiac arrhythmias and their relation to reperfusion-induced cell death , 2018, European heart journal. Acute cardiovascular care.

[32]  R. Badalzadeh,et al.  Effect of Ischemic Postconditioning on Myocardial Function and Infarct Size Following Reperfusion Injury in Diabetic Rats Pretreated With Vildagliptin , 2018, Journal of cardiovascular pharmacology and therapeutics.

[33]  M. Seishima,et al.  Autophagic adaptations in diabetic cardiomyopathy differ between type 1 and type 2 diabetes , 2015, Autophagy.

[34]  T. Eckle,et al.  Myocardial Ischemia Reperfusion Injury , 2012, Seminars in cardiothoracic and vascular anesthesia.